Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR
Abstract
:1. Introduction
2. Materials and Methods
2.1. Searching Studies and Selection Criteria
2.2. Data Extraction
2.3. Statistical Analyses
3. Results
3.1. Selection and Characteristics of the Studies
3.2. Meta-Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Bosman, F.T.; Carneiro, F.; Hruban, R.H.; Theise, N.D. WHO Classification of Tumours of the Digestive System, 4th ed.; International Agency for Research on Cancer: Lyon, France, 2010. [Google Scholar]
- Amin, M.B.; Edge, S.B.; Greene, F.L.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The AJCC Cancer Staging Manual, 8th ed.; Springer: New York, NY, USA, 2016. [Google Scholar]
- Moertel, C.G. Chemotherapy for colorectal cancer. N. Engl. J. Med. 1994, 330, 1136–1142. [Google Scholar]
- Huang, B.; Feng, Y.; Ni, M.; Chen, C.; Cai, G. Heterogeneous survival between stage IIA and stage IIIA colon cancer when different numbers of lymph nodes are harvested. Anz J. Surg. 2016. [Google Scholar] [CrossRef]
- Kim, M.J.; Jeong, S.Y.; Choi, S.J.; Ryoo, S.B.; Park, J.W.; Park, K.J.; Park, J.G. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Anna. Surg. Oncol. 2015, 22, 505–512. [Google Scholar] [CrossRef]
- Le Voyer, T.E.; Sigurdson, E.R.; Hanlon, A.L.; Mayer, R.J.; Macdonald, J.S.; Catalano, P.J.; Haller, D.G. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 2003, 21, 2912–2919. [Google Scholar] [CrossRef]
- Zhang, C.H.; Li, Y.Y.; Zhang, Q.W.; Biondi, A.; Fico, V.; Persiani, R.; Luo, M. The Prognostic Impact of the Metastatic Lymph Nodes Ratio in Colorectal Cancer. Front. Oncol. 2018, 8, 628. [Google Scholar] [CrossRef] [PubMed]
- Dedavid e Silva, T.L.; Damin, D.C. Lymph node ratio predicts tumor recurrence in stage III colon cancer. Rev. Col. Bras. Cir. 2013, 40, 463–470. [Google Scholar] [PubMed]
- Elsamany, S.A.; Alzahrani, A.S.; Mohamed, M.M.; Elmorsy, S.A.; Zekri, J.E.; Al-Shehri, A.S.; El Taani, H.A. Clinico-pathological patterns and survival outcome of colorectal cancer in young patients: Western Saudi Arabia experience. Asian Pac J. Cancer Prev. 2014, 15, 5239–5243. [Google Scholar] [CrossRef] [PubMed]
- Greenberg, R.; Itah, R.; Ghinea, R.; Sacham-Shmueli, E.; Inbar, R.; Avital, S. Metastatic lymph node ratio (LNR) as a prognostic variable in colorectal cancer patients undergoing laparoscopic resection. Tech. Coloproctol. 2011, 15, 273–279. [Google Scholar] [CrossRef] [PubMed]
- Hong, K.D.; Lee, S.I.; Moon, H.Y. Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer. J. Surg. Oncol. 2011, 103, 406–410. [Google Scholar] [CrossRef] [PubMed]
- Leonard, D.; Remue, C.; Abbes Orabi, N.; van Maanen, A.; Danse, E.; Dragean, A. Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: Results from a single referral centre. Colorectal. Dis. 2016, 18, O175–O184. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.J.; Lin, P.C.; Lin, C.C.; Wang, H.S.; Yang, S.H.; Jiang, J.K. The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients. World J. Surg. 2013, 37, 1927–1933. [Google Scholar] [CrossRef] [PubMed]
- Park, I.J.; Yu, C.S.; Lim, S.B.; Yoon, Y.S.; Kim, C.W.; Kim, T.W. Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy. World J. Gastroenterol. 2015, 21, 3274–3281. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Esquivel, A.; Juárez, M.; González, I.; Porras, J.; Rodriguez, L. Prognosis impact of the lymph node ratio in patients with colon adenocarcinoma: A single-centre experience. J. Gastrointest. Cancer 2014, 45, 133–136. [Google Scholar] [CrossRef] [PubMed]
- Rao, A.; Dadras, M.; Razzak, M.A.; Ahmad, K.; Vijayasekar, C. Effect of Lymph Node Retrieval and Ratio on the Long-Term Survival and Recurrence of Colon Cancer. J. Coll. Physicians. Surg. Pak. 2016, 26, 467–470. [Google Scholar]
- Schiffmann, L.; Eiken, A.K.; Gock, M.; Klar, E. Is the lymph node ratio superior to the Union for International Cancer Control (UICC) TNM system in prognosis of colon cancer? World J. Surg. Oncol. 2013, 11, 79. [Google Scholar] [CrossRef]
- Sugimoto, K.; Sakamoto, K.; Tomiki, Y.; Goto, M.; Kojima, Y.; Komiyama, H. The validity of predicting prognosis by the lymph node ratio in node-positive colon cancer. Dig. Surg. 2013, 30, 368–374. [Google Scholar] [CrossRef]
- Sugimoto, K.; Sakamoto, K.; Tomiki, Y.; Goto, M.; Kotake, K.; Sugihara, K. Proposal of new classification for stage III colon cancer based on the lymph node ratio: Analysis of 4,172 patients from multi-institutional database in Japan. Ann. Surg. Oncol. 2015, 22, 528–534. [Google Scholar] [CrossRef]
- Vaccaro, C.A.; Im, V.; Rossi, G.L.; Quintana, G.O.; Benati, M.L.; Perez de Arenaza, D. Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis. Colon. Rectum. 2009, 52, 1244–1250. [Google Scholar] [CrossRef]
- Cook, D.A.; Reed, D.A. Appraising the quality of medical education research methods: The Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad. Med. J. Assoc. Am. Med. Coll. 2015, 90, 1067–1076. [Google Scholar] [CrossRef]
- Yusuf, S.; Peto, R.; Lewis, J.; Collins, R.; Sleight, P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog. Cardiovasc. Dis. 1985, 27, 335–371. [Google Scholar] [CrossRef]
- Schumacher, P.; Dineen, S.; Barnett, C., Jr.; Fleming, J.; Anthony, T. The metastatic lymph node ratio predicts survival in colon cancer. Am. J. Surg. 2007, 194, 827–831. [Google Scholar] [CrossRef] [PubMed]
- Baxter, N.N.; Virnig, D.J.; Rothenberger, D.A.; Morris, A.M.; Jessurun, J.; Virnig, B.A. Lymph node evaluation in colorectal cancer patients: A population-based study. J. Natl. Cancer Inst. 2005, 97, 219–225. [Google Scholar] [CrossRef] [PubMed]
- Chang, G.J.; Rodriguez-Bigas, M.A.; Skibber, J.M.; Moyer, V.A. Lymph node evaluation and survival after curative resection of colon cancer: Systematic review. J. Natl. Cancer Inst. 2007, 99, 433–441. [Google Scholar] [CrossRef] [PubMed]
- Mamounas, E.; Wieand, S.; Wolmark, N.; Bear, H.D.; Atkins, J.N.; Song, K. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 1999, 17, 1349–1355. [Google Scholar] [CrossRef] [PubMed]
- Vather, R.; Sammour, T.; Kahokehr, A.; Connolly, A.B.; Hill, A.G. Lymph node evaluation and long-term survival in Stage II and Stage III colon cancer: A national study. Ann. Surg. Oncol. 2009, 16, 585–593. [Google Scholar] [CrossRef]
- Johnson, P.M.; Malatjalian, D.; Porter, G.A. A. Adequacy of nodal harvest in colorectal cancer: A consecutive cohort study. J. Gastrointest. Surg. 2002, 6, 883–888. [Google Scholar] [CrossRef]
- Rosenberg, R.; Friederichs, J.; Schuster, T.; Gertler, R.; Maak, M.; Becker, K. Prognosis of patients with colorectal cancer is associated with lymph node ratio: A single-center analysis of 3,026 patients over a 25-year time period. Ann. Surg. 2008, 248, 968–978. [Google Scholar] [CrossRef]
- Berger, A.C.; Sigurdson, E.R.; Le Voyer, T.; Hanlon, A.; Mayer, R.J.; Macdonald, J.S. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J. Clin. Oncol. 2005, 23, 8706–8712. [Google Scholar] [CrossRef]
- Inoue, K.; Nakane, Y.; Iiyama, H.; Sato, M.; Kanbara, T.; Nakai, K. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann. Surg. Oncol. 2002, 9, 27–34. [Google Scholar] [CrossRef]
- Rodriguez Santiago, J.M.; Munoz, E.; Marti, M.; Quintana, S.; Veloso, E.; Marco, C. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur. J. Surg. Oncol. 2005, 31, 59–66. [Google Scholar] [CrossRef]
- Bando, E.; Yonemura, Y.; Taniguchi, K.; Fushida, S.; Fujimura, T.; Miwa, K. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann. Surg. Oncol. 2002, 9, 775–784. [Google Scholar] [CrossRef] [PubMed]
- Van der Wal, B.C.; Butzelaar, R.M.; van der Meij, S.; Boermeester, M.A. Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur. J. Surg. Oncol. 2004, 28, 481–489. [Google Scholar] [CrossRef]
- Berger, A.C.; Watson, J.C.; Ross, E.A.; Hoffman, J.P. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. Surg. 2004, 70, 235–240. [Google Scholar] [PubMed]
Study, Year | Location | Study Design † | Tumor Stage | Tumor Location | Age (SD) | Harvested Number of LN (SD) | mLNR Criteria | Number of Patients | ||
---|---|---|---|---|---|---|---|---|---|---|
LNM | High mLNR | Low mLNR | ||||||||
Dedavid, 2013 [8] | Brazil | R/SI | Stage III | Colorectum | 62.4 (7.3) | 19.3 (2.0) | 0.15 | 70 | 32 | 38 |
Elsamany, 2014 [9] | Egypt | R/LC | Stage I–III | Colorectum | ND | ND | 0.2 | 84 | 47 | 37 |
Greenberg, 2011 [10] | Israel | R/SI | Stage III | Colorectum | ND | 20.3 (8.3) | 0.13 | 65 | 35 | 30 |
Hong, 2011 [11] | Korea | R/SI | Stage III | Colon | ND | 50.7 (21.7) | 0.1638 | 130 | 33 | 97 |
Leonard, 2016 [12] | Belgium | R/SI | All stage (III, n = 145) | Rectum | 65.6 (12.8) | 12.8 (8.8) | 0.2 | 357 | ND | ND |
Lu, 2013 [13] | Taiwan | R/SI | Stage III | Colorectum | 64.9 (12.8) | 19.8 (9.5) | 0.17 | 612 | 322 | 290 |
Park, 2015 [14] | Korea | R/SI | Stage III | Rectum | 54.0 (10.3) | 18.2 (8.5) | 0.25 | 724 | ND | ND |
Ramos-Esquivel, 2014 [15] | Costa Rica | R/SI | All stage (III, n = 29) | Colon | 62.8 (17.7) | 12.0 (2.7) | 0.25 | 39 | 23 | 16 |
Rao, 2016 [16] | UK | R/SI | Duke C | Colorectum | 72.0 (10.9) | 20.1 (8.6) | 0.125 | 147 | 81 | 66 |
Schiffmann, 2013 [17] | Germany | R/SI | Stage III | Colon | 67.7 (9.5) | 23.2 (9.3) | 0.2 | 142 | 54 | 88 |
Sugimoto, 2013 [18] | Japan | R/SI | Stage III * | Colon | 62.5 (10.0) | 36.6 (17.3) | 0.3 | 311 | 55 | 256 |
Sugimoto, 2015 [19] | Japan | R/MIDJ | Stage III | Colon | 60.2 (12.2) | 41.3 (20.2) | 0.18 | 4172 | 1428 | 2744 |
Vaccaro, 2009 [20] | Argentina | R/SI | Stage III | Colon | 67.4 (12.6) | 20.0 (0.3) | 0.25 | 362 | 92 | 270 |
Zhang, 2018 [7] | USA | R/SEER | Stage III | Colon | 68.1 (13.5) | 14.2 (9.6) | 0.25 | 83,059 | 48,013 | 35,046 |
Number of Subset | Fixed Effect (95% CI) | Heterogeneity Test (p-Value) | Random Effect (95% CI) | Egger’s Test (p-Value) | |
---|---|---|---|---|---|
Overall | 9 | 1.535 (1.509, 1.562) | 0.072 | 1.617 (1.393, 1.877) | 0.093 |
Tumor stage | |||||
Stage III | 5 | 1.536 (1.334, 1.769) | 0.098 | 1.730 (1.266, 2.362) | 0.108 |
High mLNR criteria | |||||
mLNR < 0.2 | 5 | 1.534 (1.507, 1.561) | 0.294 | 1.521 (1.394, 1.661) | 0.601 |
mLNR ≤ 0.2 | 6 | 1.534 (1.508, 1.561) | 0.084 | 1.557 (1.343, 1.805) | 0.294 |
mLNR ≥ 0.2 | 3 | 2.770 (1.765, 4.347) | 0.433 | 2.770 (1.765, 4.347) | 0.398 |
Colon | 2 | 2.412 (1.463, 3.977) | 0.741 | 2.412 (1.463, 3.977) | NA |
Rectum | 1 | 5.040 (1.780, 14.270) | 1.000 | 5.040 (1.780, 14.270) | NA |
Number of Subset | Fixed Effect (95% CI) | Heterogeneity Test (p-Value) | Random Effect (95% CI) | Egger’s Test (p-Value) | |
---|---|---|---|---|---|
Overall | 11 | 2.209 (1.883, 2.591) | 0.129 | 2.345 (1.879, 2.926) | 0.020 |
Tumor stage | |||||
Stage III | 6 | 2.246 (1.795, 2.809) | 0.091 | 2.451 (1.719, 3.494) | 0.165 |
High mLNR criteria | |||||
mLNR < 0.2 | 4 | 1.976 (1.425, 2.740) | 0.056 | 2.878 (1.401, 5.912) | 0.061 |
mLNR ≤ 0.2 | 7 | 2.131 (1.667, 2.723) | 0.081 | 2.497 (1.706, 3.657) | 0.015 |
mLNR ≥ 0.2 | 7 | 2.287 (1.905, 2.747) | 0.324 | 2.322 (1.885, 2.861) | 0.160 |
Colon | 4 | 2.496 (1.917, 3.249) | 0.495 | 2.496 (1.917, 3.249) | 0.490 |
Rectum | 2 | 2.158 (1.645, 2.831) | 0.060 | 2.730 (1.226, 6.076) | NA |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pyo, J.S.; Kim, J.H.; Lee, S.Y.; Baek, T.H.; Kang, D.W. Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR. Medicina 2019, 55, 673. https://doi.org/10.3390/medicina55100673
Pyo JS, Kim JH, Lee SY, Baek TH, Kang DW. Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR. Medicina. 2019; 55(10):673. https://doi.org/10.3390/medicina55100673
Chicago/Turabian StylePyo, Jung Soo, Joo Heon Kim, Seung Yun Lee, Tae Hwa Baek, and Dong Wook Kang. 2019. "Metastatic Lymph Node Ratio (mLNR) is a Useful Parameter in the Prognosis of Colorectal Cancer; A Meta-Analysis for the Prognostic Role of mLNR" Medicina 55, no. 10: 673. https://doi.org/10.3390/medicina55100673